Shelia M. Violette - 24 Feb 2026 Form 4 Insider Report for Q32 Bio Inc. (QTTB)

Reporting relationship: Chief Scientific Officer
Issuer ticker: QTTB
Reported as of: 24 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Mar 2026, 19:00:05 UTC
Prior SEC filing: 28 Aug 2025
Next SEC filing: 27 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Eric Bell, Attorney-in-Fact

Key filing fact

Shelia M. Violette filed Form 4 for Q32 Bio Inc. (QTTB) on 20 Mar 2026.

Key facts

This page summarizes Shelia M. Violette's Form 4 filing for Q32 Bio Inc. (QTTB).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Mar 2026, 19:00.

Change

Previous filing in this sequence was filed on 28 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002016144 Primary reporting owner

Violette Shelia M.

Relationship: Chief Scientific Officer
Address: Q32 BIO INC., 830 WINTER STREET, WALTHAM
Signature: /s/ Eric Bell, Attorney-in-Fact
Signature date: 20 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

QTTB transaction

Common Stock

Award

Transaction value
Shares: +37,500
Change %: +67%
Price: $0.000000^*
Shares after: 93,069
Date: 24 Feb 2026
Ownership: Direct
Footnotes: F1

QTTB holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 36,277
Date: 24 Feb 2026
Ownership: By Violette Holdings LLC
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The restricted stock units ("RSUs") vest in four equal installments, 25% shall vest 6 months from February 24, 2026 (the "Grant Date"), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock.

Footnote F2

Shares held by Violette Holdings LLC ("Violette Holdings"). The Reporting Person is a manager of Violette Holdings and disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.